App-Quantinova.ai

Pan-enteric capsule to assess treatment effects of vedolizumab in IBD patients: A 1 year proof of concept study

Thakor, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Entyvio

Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe

Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.

Meredith, J.J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Metronidazole

High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Karki, C - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North

Sands, B.E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Incorporating HLADQA1*05 in pre-biologic screening in IBD patients initiating biologic therapies

Aleman Gonzalez, H - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic review

Gordon, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tacrolimus

The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease

Mckirdy, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring

Shields, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Post-transplant diabetes mellitus

Adalimumab

Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients

Witjes, C - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).

Duff, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study

Iqbal, N - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Perianal fistulising Crohn’s disease

N/A

Risankizumab in Crohn's disease: Real World Experience from a Pre-Approval Access Program

Dawson, P - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Risankizumab

Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium

Wong, S.Y - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Monitoring of Thiopurines and Methotrexate in Inflammatory Bowel Disease: Are we Monitoring Too Frequently? A Cross Sectional Study.

Liao, Y.W - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

6-mercaptopurine

Keeping it simple: How a streamlined referrals process reduces the time taken to initiate biologic therapy

Granger, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Entyvio

PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis

Saifuddin, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenance

Pans, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

ABT-494

Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease

Aleman Gonzalez, H - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas

Lloyd, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Infliximab

Filters

45280 Abstracts